Skip to main
IMVT
IMVT logo

Immunovant Inc (IMVT) Stock Forecast & Price Target

Immunovant Inc (IMVT) Analyst Ratings

Based on 22 analyst ratings
Buy
Strong Buy 50%
Buy 36%
Hold 9%
Sell 5%
Strong Sell 0%

Bulls say

Immunovant Inc. is focused on its lead candidate, IMVT-1402, a potential IgG antibody inhibitor with promising prospects in treating autoimmune diseases. The company's strategic investment in research and development, reflected by a 49.7% year-over-year increase in G&A expenses, indicates a robust commitment to advancing its product pipeline, particularly in the large market for autoimmune conditions. With projected global peak sales of $775 million in generalized myasthenia gravis (gMG) based on conservative market penetration assumptions and the advantages of self-administration through an auto-injector, Immunovant’s business model suggests a favorable outlook for capturing market share and increasing profitability.

Bears say

Immunovant Inc experienced a significant year-over-year increase of 95.5% in research and development (R&D) expenses, amounting to $94.5 million, which fell short of the company's estimated expenses and indicates a growing financial burden. Additionally, the company reported a net loss of $111.1 million for the fiscal 3Q24, translating to a loss per share of $0.76, which not only exceeded previous estimates but also highlighted a deterioration in performance compared to the prior year's loss per share of $0.36. Furthermore, the emerging understanding that other antibody isotypes contribute to autoimmune diseases raises concerns regarding the efficacy of Immunovant's FcRn inhibition approach, suggesting potential challenges ahead in clinical development and increased operational risks.

Immunovant Inc (IMVT) has been analyzed by 22 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 36% recommend Buy, 9% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunovant Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunovant Inc (IMVT) Forecast

Analysts have given Immunovant Inc (IMVT) a Buy based on their latest research and market trends.

According to 22 analysts, Immunovant Inc (IMVT) has a Buy consensus rating as of Jul 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.27, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.27, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunovant Inc (IMVT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.